Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V
Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.

In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. There are also biosimilars of bevacizumab available, such as bevacizumab-awwb, bevacizumab-maly, and bevacizumab-adcd.

Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.

Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Associated Conditions
Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Associated Therapies
First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

First Posted Date
2006-11-10
Last Posted Date
2017-03-01
Lead Sponsor
Pamela L. Kunz
Target Recruit Count
40
Registration Number
NCT00398320
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

First Posted Date
2006-11-01
Last Posted Date
2017-08-01
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
38
Registration Number
NCT00394433
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-10-31
Last Posted Date
2019-11-25
Lead Sponsor
Celgene
Target Recruit Count
50
Registration Number
NCT00394082

A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment

Phase 1
Completed
Conditions
First Posted Date
2006-10-27
Last Posted Date
2014-09-22
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
11
Registration Number
NCT00393497
Locations
🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

First Posted Date
2006-10-26
Last Posted Date
2013-02-22
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
60
Registration Number
NCT00392704
Locations
🇺🇸

Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

and more 4 locations

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

First Posted Date
2006-10-26
Last Posted Date
2013-09-20
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
29
Registration Number
NCT00392392
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 3 locations

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

First Posted Date
2006-10-26
Last Posted Date
2022-03-02
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
62
Registration Number
NCT00393068
Locations
🇺🇸

Northeast Georgia Medical Center, Gainesville, Georgia, United States

🇺🇸

Oncology Hematology Care, Cincinnati, Ohio, United States

🇺🇸

Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

First Posted Date
2006-10-26
Last Posted Date
2017-04-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
36
Registration Number
NCT00392665
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

First Posted Date
2006-10-05
Last Posted Date
2017-04-14
Lead Sponsor
AstraZeneca
Target Recruit Count
1814
Registration Number
NCT00384176
Locations
🇻🇳

Research Site, Ho Chi Minh, Vietnam

© Copyright 2024. All Rights Reserved by MedPath